Peter Thiel Invests $12 Million In Psychedelic Drug Manufacturer

Peter Thiel Invests $12 Million In Psychedelic Drug Manufacturer

Billionaire tech investor Peter Thiel is the latest to join the booming psychedelic industry. The PayPal co-founder backed Berlin’s ATAI Life Sciences in a $125 million series C funding round. Thiel’s investment firm, Thiel Capital,…

Psychedelic stocks: the next BILLION dollar industry (2 mushroom stocks you MUST own in 2020)

Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Psychedelic Tech Company Cybin Brings In a $45 Million

Psychedelic Tech Company Cybin Brings In a $45 Million (CAD) Funding Round

Canadian pharmaceutical therapies company Cybin announced $45 million (CAD) in gross proceeds on a private placement of 60,000,000 subscription receipts as part of a new funding round. The company will use the funds to further expand its development…
Dr. Andrew Weil Joins Advisory Board for Psychedelic Therapy Platform

Dr. Andrew Weil Joins Advisory Board for Psychedelic Therapy Platform Field Trip

Acclaimed integrative medicine pioneer, Dr. Andrew Weil, has joined the advisory board for psychedelic therapy platform Field Trip Health. “I am extremely pleased to be joining the medical advisory board at Field Trip,” Dr. Weil…
Field Trip Is the Latest Psychedelic Therapy Company to Go Public

Field Trip Is the Latest Psychedelic Therapy Company to Go Public

Another psychedelic therapy-based company has gone public. Toronto-based Field Trip Health Ltd., which operates the mobile therapy app Trip, is now trading on the Canadian Securities Exchange under the symbol FTRP. Psychedelic therapy for…
Ibogaine and LSD Producer MindMed Applies for Nasdaq Up-Listing

Ibogaine and LSD Producer MindMed Applies for Nasdaq Up-Listing

Just days after UK-based psychedelic developer Compass Pathways went public, New York-based MindMed has applied for a Nasdaq up-listing. The company, valued at $190 million,  is already listed on Canada’s NEO exchange. MindMed…
Compass Pathways IPO Brings $1 Billion Valuation

Compass Pathways IPO Brings $1 Billion Valuation

UK-based Compass Pathways led a groundbreaking IPO last week. Share prices spiked 71 percent to nearly $30 after the initial offering of 7.5 million shares, which launched at $17 each. Current value of the company based on its 34 million shares…
Investors Are Betting On Psychedelics

Why Investors Are Betting On Psychedelics

While they’ve historically brought the risk of long jail sentences, psychedelics are now bringing another long-term scenario: big-time investments. The potential for psychedelics in treating mental disorders such as depression, suicidal…
The Psychedelic Medicine Association

The Psychedelic Medicine Association Launches to Align the Industry

A first of its kind, The Psychedelic Medicine Association (PMA) is set to launch on September 29th. The association aligns medical establishments, patients, and industry leaders in the advancement of psychedelic therapy. “We want physicians…
Quick-Dissolve Strips to Psychedelics

New Partnership Will Bring Quick-Dissolve Strips to Psychedelics

Psychedelic drugs could soon have a standardized, and much faster delivery method with the announcement last month that ATAI Life Sciences AG and IntelGenx have entered into an agreement to develop polymeric film technologies. The…